Dynavax Technologies Co. (NASDAQ:DVAX) Shares Purchased by Peregrine Capital Management LLC

Peregrine Capital Management LLC increased its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 1.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 654,620 shares of the biopharmaceutical company’s stock after buying an additional 11,687 shares during the period. Peregrine Capital Management LLC’s holdings in Dynavax Technologies were worth $8,359,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC increased its position in shares of Dynavax Technologies by 19.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company’s stock valued at $83,000 after buying an additional 1,076 shares in the last quarter. Sanctuary Advisors LLC grew its stake in Dynavax Technologies by 6.3% in the 4th quarter. Sanctuary Advisors LLC now owns 18,836 shares of the biopharmaceutical company’s stock valued at $245,000 after acquiring an additional 1,109 shares during the last quarter. GAMMA Investing LLC increased its holdings in Dynavax Technologies by 55.1% during the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock valued at $52,000 after acquiring an additional 1,457 shares in the last quarter. US Bancorp DE raised its position in Dynavax Technologies by 291.4% during the third quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 2,034 shares during the last quarter. Finally, Parkman Healthcare Partners LLC lifted its holdings in shares of Dynavax Technologies by 1.2% in the third quarter. Parkman Healthcare Partners LLC now owns 219,451 shares of the biopharmaceutical company’s stock valued at $2,445,000 after purchasing an additional 2,629 shares in the last quarter. 96.96% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on DVAX shares. StockNews.com downgraded Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Wednesday, February 12th. The Goldman Sachs Group cut Dynavax Technologies from a “neutral” rating to a “sell” rating and cut their price target for the stock from $15.00 to $12.00 in a report on Tuesday, February 11th. Finally, HC Wainwright increased their price objective on Dynavax Technologies from $29.00 to $31.00 and gave the company a “buy” rating in a research note on Tuesday, January 14th.

Dynavax Technologies Stock Performance

NASDAQ:DVAX opened at $12.93 on Wednesday. Dynavax Technologies Co. has a 1-year low of $9.74 and a 1-year high of $13.89. The firm has a 50 day simple moving average of $12.80 and a 200-day simple moving average of $11.96. The firm has a market cap of $1.70 billion, a PE ratio of 99.47 and a beta of 1.32. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.